6505--Streamlined Domestic Nonavailability Waiver Determination - Pharmaceuticals

The Department of Veterans Affairs is seeking comments on a Buy American domestic nonavailability waiver determination for pharmaceuticals. The VA has conducted market research and found that many pharmaceuticals are not domestically produced. The VA is planning to use a single "streamlined nonavailability waiver determination" for fiscal year 2026 procurements of 10 specified pharmaceutical products. The goal is to promote accountable and transparent procurements while ensuring timely procurement of pharmaceuticals to meet patient care needs. Some key points to consider: • The VA is committed to maximizing the use of pharmaceuticals manufactured in the United States. • The VA has identified 10 pharmaceuticals that are not available in sufficient and reasonably available commercial quantities of satisfactory quality within the U.S. • The streamlined nonavailability waiver determination will reduce the volume of individual waiver determinations and increase procurement efficiencies. • The VA is seeking comments on the proposed waiver determination.